Results 61 to 70 of about 58,504 (176)

Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

BMC Cancer
Background Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable or metastatic advanced gastric cancer (AGC)
Sung Hee Lim, Keun-Wook Lee, Jae-Joon Kim, Hyeon-Su Im, In-Ho Kim, Hye Sook Han, Dong-Hoe Koo, Jang Ho Cho, Chi Hoon Maeng, Min-Young Lee, Hyo Jin Lee, Jwa Hoon Kim, Sang Gon Park, Joo Young Jung, Seong-Hoon Shin, Ki Hyang Kim, Hyeyeong Kim, So Yeon Oh, Minsu Kang, Minkyu Jung, Sun Young Rha   +20 more
doaj   +1 more source

P-glycoprotein-dependent pharmacokinetics of irinotecan and its active metabolite, SN-38 in rats: Effect of verapamil

ADMET and DMPK, 2015
We have recently demonstrated that the oral bioavailability of irinotecan (80 mg/kg) can be increased at least 7-fold by co-administration of the P-gp blocker verapamil (25 mg/kg, Oral).
Tripta Garg, Manu Jaggi, Roop K. Khar, Sushama Talegaonkar   +3 more
doaj   +1 more source

ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients

Frontiers in Pharmacology, 2020
Irinotecan is widely used in the treatment of metastatic colorectal cancer (mCRC) despite its severe toxicities. Toxicity is often associated with the UGT1A1*28/*28 genotype.
Pau Riera, Pau Riera, Pau Riera, Alícia Artigas-Baleri, Juliana Salazar, Ana Sebio, Anna C. Virgili, María Jesús Arranz, David Páez, David Páez   +9 more
doaj   +1 more source

Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review

Pharmaceutics
Background/Objectives: Irinotecan is used in monotherapy or combined with other drugs for treating different cancer streams. SN-38, the active metabolite of irinotecan, is 70% inactivated by the uridine diphosphate (UDP) glucuronosyltransferase family 1 ...
Xando Díaz-Villamarín, María Teresa Nieto-Sánchez, María Martínez-Pérez, Paula Novo-González, Emilio Fernández-Varón, Alicia Torres-García, Beatriz González Astorga, Isabel Blancas, José Cabeza-Barrera, Rocío Morón   +9 more
doaj   +1 more source

Optimization of irinotecan chronotherapy with P-glycoprotein inhibition

, 2014
The relevance of P-glycoprotein (P-gp) for irinotecan chronopharmacology was investigated in female B6D2F1 mice. A three-fold 24 h change in the mRNA expression of Abcb1b was demonstrated in ileum mucosa, with a maximum at Zeitgeber Time (ZT) 15 (p < 0 ...
VAN DER HORST, Gijsbertus T. J., Levi, Francis, van der Horst, Gijsbertus T. J., Okyar, Alper, Filipski, Elisabeth, Berland, Elodie, Ozturk, Narin, Guettier, Catherine, Lévi, Francis A., Okyar, A, Levi, F, Ozturk, N, Berland, E, van der Horst, Bert, Guettier, C, Filipski, E   +15 more
core   +2 more sources

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment

, 2017
Masashi Takano1 Toru Sugiyama2 1Department of Clinical Oncology, National Defense Medical College Hospital, Tokorozawa, Saitama, 2Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Iwate, Japan Abstract: Mutations in the UGT1A1 ...
Takano M, Sugiyama T
core  

Irinotecan combined with KML001 has an additive inhibitory effect in CT26 isograft models.

, 2013
(A) At 24 h after being injected with irinotecan (once weekly), injected with KML001 (once weekly). (B) At 24 h and 72 h after being injected with irinotecan (once weekly), injected with KML001 (twice weekly).
Ho-Taek Song (289429), Jin Seo (289425), Young Han Lee (289426), Seung Ju Lee (289419), Young Joo Min (289431), Hyun Jin Park (289424), Wha Ja Cho (289423), Chang Hoon Moon (289417), Jeong Woo Park (192399), HeeJeong Cha (289422), Ho Yong Lee (289420), Jong Cheol Lee (289421)   +11 more
core   +1 more source

Therapeutic Dose Response of Acoustic Cluster Therapy in Combination With Irinotecan for the Treatment of Human Colon Cancer in Mice

Frontiers in Pharmacology, 2019
Introduction: Acoustic Cluster Therapy (ACT) comprises coadministration of a formulation containing microbubble-microdroplet clusters (PS101) together with a regular medicinal drug and local ultrasound (US) insonation of the targeted pathological tissue.
Nigel Bush, Andrew Healey, Anant Shah, Gary Box, Vladimir Kirkin, Spiros Kotopoulis, Svein Kvåle, Per Christian Sontum, Jeffrey Bamber   +8 more
doaj   +1 more source

Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview

, 2001
PURPOSE AND METHODS: For more than three decades, the therapeutic options for patients with advanced colorectal cancer have almost exclusively been based on fluoropyrimidines. With the recognition that topoisomerase-I (TOP-I) is an important therapeutic
Wolf Achterrath, Udo Vanhoefer, Andreas Harstrick, Siegfried Seeber, Shousong Cao, Youcef M. Rustum   +5 more
core   +1 more source

Irinotecan-induced colitis

, 2005
Irinotecan (CPT-11) is a chemotherapeutic drug used to treat tumors by acting on malignant cells through inhibition of DNA topoisomerase I and inducing premature apoptosis.
Bouzourene, H., Sandmeier, D., Chaubert, P.   +2 more
core   +1 more source